Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 462 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Aggressive Behavior Clear all
Completed No phase listed Observational

Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM

NCT04695431
View directory record Official record
Conditions
Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematological Neoplasm, Mast Cell Leukemia
Interventions
Not listed
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Palo Alto, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Jul 23, 2026, 3:13 AM EDT
Completed Phase 4 Interventional

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

NCT00228046
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Oppositional Defiant Disorder
Interventions
Divalproex Sodium, Methylphenidate, Dextroamphetamine, Mixed Amphetamine Salts, Family Counseling, Behavior Management Training with Parents
Drug · Behavioral
Lead sponsor
Stony Brook University
Other
Eligibility
6 Years to 14 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New Hyde Park, New York • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Jul 23, 2026, 3:13 AM EDT
Recruiting Phase 2 Interventional

Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)

NCT07162480
View directory record Official record
Conditions
Adenoid Cystic Carcinoma
Interventions
P-Sam
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 23, 2026, 3:13 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01364662
View directory record Official record
Conditions
Impulsive Aggression Comorbid With ADHD
Interventions
SPN-810, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
27
States / cities
Dothan, Alabama • Los Angeles, California • Santa Ana, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Jul 23, 2026, 3:13 AM EDT
Completed Phase 2 Interventional

A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

NCT00038545
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Filgrastim SD/01, Paclitaxel, Topotecan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Jul 23, 2026, 3:13 AM EDT
Recruiting Not applicable Interventional

Impact of Bright Light Therapy on Prader-Willi Syndrome

NCT05939453
View directory record Official record
Conditions
Prader-Willi Syndrome, Excessive Daytime Sleepiness, Hyperphagia, Body Weight, Mood, Behavior
Interventions
Sham Light, Bright Light Therapy
Other
Lead sponsor
Maimonides Medical Center
Other
Eligibility
6 Years to 88 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 23, 2026, 3:13 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment

NCT03597503
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
SPN-810, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
38
States / cities
Culver City, California • Orange, California • Colorado Springs, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Jul 23, 2026, 3:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

CPI Training for Parents of Children With ASD

NCT03537261
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Parent-based Crisis Prevention Institute (CPI) physical management training program (P-CPI)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 12 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Jul 23, 2026, 3:13 AM EDT
Active, not recruiting Phase 1 Interventional

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

NCT01840566
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Carmustine, Etoposide, Cytarabine, Melphalan, Pegfilgrastim, 19-28z T CELLS, Autologous Stem Cell Transplantation
Drug · Biological · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 23, 2026, 3:13 AM EDT
Completed Not applicable Interventional Results available

Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study

NCT00779324
View directory record Official record
Conditions
Brain Injury, Aggression
Interventions
Amantadine Hydrochloride, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
16 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Jul 23, 2026, 3:13 AM EDT
Terminated Phase 1 Interventional

A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma

NCT02702141
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, DLBCL, Diffuse Large B-cell Lymphoma, Grade 3 Follicular Lymphoma
Interventions
SGN-CD19B
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2018 · Synced Jul 23, 2026, 3:13 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Interventions
Zilovertamab vedotin, Nemtabrutinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
20
States / cities
Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 3:13 AM EDT
Completed Not applicable Interventional Results available

Group CBT for Aggression in Veterans

NCT02233517
View directory record Official record
Conditions
Aggression, Anger, Posttraumatic Stress Disorder
Interventions
Cognitive Behavioral Therapy, Present Centered Therapy
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Jul 23, 2026, 3:13 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of ACT OUT! Social Issue Theater on Youth and Adolescents

NCT04097496
View directory record Official record
Conditions
Social Competence, Bullying
Interventions
Act Out! Intervention
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
Not listed
Enrollment
1,537 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Jul 23, 2026, 3:13 AM EDT
Completed No phase listed Observational

Study of Electroconvulsive Therapy (ECT) Treatment for Agitation and Aggression in Dementia

NCT01856010
View directory record Official record
Conditions
Dementia, Aggression, Agitation
Interventions
ECT treatment, Standard Care (Non-ECT group)
Other
Lead sponsor
Pine Rest Christian Mental Health Services
Other
Eligibility
50 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Belmont, Massachusetts • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Jul 23, 2026, 3:13 AM EDT
Completed Phase 2 Interventional

Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

NCT00278382
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
Interventions
sorafenib tosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Jul 23, 2026, 3:13 AM EDT
Recruiting Not applicable Interventional

Flourish in Schools Pilot Study

NCT07506525
View directory record Official record
Conditions
Psychological Distress, Suicidal Ideation
Interventions
Flourish
Device
Lead sponsor
Candice Biernesser
Other
Eligibility
11 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Bay Village, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 23, 2026, 3:13 AM EDT
Completed No phase listed Observational

Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's Lymphoma

NCT00026910
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 3:13 AM EDT
Completed Not applicable Interventional

A Brief Intervention to Prevent Adolescent Dating Aggression Perpetration

NCT02080923
View directory record Official record
Conditions
Offensive Aggression, Sexual Aggression, Dating Violence Perpetration and Victimization
Interventions
Brief Motivational Interview
Behavioral
Lead sponsor
Boston University
Other
Eligibility
15 Years to 19 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Jul 23, 2026, 3:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing School Safety Officers' Effectiveness Through Online Professional and Job Embedded Coaching

NCT03339648
View directory record Official record
Conditions
Bullying, School Fear, Professional Role
Interventions
Professional Development Enhancement
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Jul 23, 2026, 3:13 AM EDT
Terminated Phase 3 Interventional Results available

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

NCT02366663
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
90-Yttrium Ibritumomab tiuxetan, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous Hematopoietic Stem Cell Transplant, Rituximab
Radiation · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Jul 23, 2026, 3:13 AM EDT
Recruiting Phase 1 Interventional

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

NCT04231877
View directory record Official record
Conditions
Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Gray-Zone Lymphoma
Interventions
Polatuzumab Vedotin, Rituximab, Prednisone, Etoposide, Doxorubicin, Cyclophosphamide, Glofitamab, Multigated Acquisition Scan, Echocardiography Test, FDG-Positron Emission Tomography, Computed Tomography, Bone Marrow Biopsy, Biospecimen Collection, Bone Marrow Aspiration
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jul 23, 2026, 3:13 AM EDT
Recruiting Phase 2 Interventional

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

NCT06238648
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Epcoritamab, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography
Procedure · Biological · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
6
States / cities
Rochester, Minnesota • St Louis, Missouri • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Jul 23, 2026, 3:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

NCT00290706
View directory record Official record
Conditions
Lymphoma
Interventions
bortezomib, gemcitabine hydrochloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Jul 23, 2026, 3:13 AM EDT